Oak Grove Capital’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$390K Hold
2,800
0.03% 78
2025
Q4
$344K Hold
2,800
0.04% 71
2025
Q3
$311K Sell
2,800
-2,000
-42% -$227K 0.04% 67
2025
Q2
$532K Sell
4,800
-7,200
-60% -$766K 0.09% 51
2025
Q1
$1.34M Hold
12,000
0.28% 42
2024
Q4
$1.11M Hold
12,000
0.17% 46
2024
Q3
$1.01M Buy
12,000
+1,400
+13% +$107K 0.16% 42
2024
Q2
$727K Buy
+10,600
New +$707K 0.13% 41
2022
Q2
Sell
-6,400
Closed -$380K 73
2022
Q1
$380K Sell
6,400
-4,450
-41% -$284K 0.08% 64
2021
Q4
$788K Sell
10,850
-3,800
-26% -$262K 0.14% 62
2021
Q3
$1.02M Sell
14,650
-25,531
-64% -$1.79M 0.22% 54
2021
Q2
$2.77M Sell
40,181
-37,171
-48% -$2.48M 0.62% 38
2021
Q1
$5M Sell
77,352
-1,600
-2% -$103K 1.4% 26
2020
Q4
$4.6M Buy
78,952
+12,602
+19% +$760K 1.5% 27
2020
Q3
$4.19M Buy
66,350
+30,171
+83% +$2.09M 1.98% 17
2020
Q2
$2.78M Sell
36,179
-59,850
-62% -$4.59M 1.68% 16
2020
Q1
$7.18M Sell
96,029
-102,496
-52% -$7.08M 4.64% 5
2019
Q4
$12.9M Sell
198,525
-3,350
-2% -$218K 5.04% 3
2019
Q3
$12.8M Buy
201,875
+96,100
+91% +$6.28M 5.55% 4
2019
Q2
$7.15M Buy
105,775
+52,800
+100% +$3.47M 3.82% 6
2019
Q1
$3.44M Buy
52,975
+22,350
+73% +$1.49M 2.17% 15
2018
Q4
$1.92M Buy
30,625
+13,300
+77% +$930K 1.71% 16
2018
Q3
$1.34M Sell
17,325
-500
-3% -$37.8K 1.15% 22
2018
Q2
$1.26M Buy
17,825
+2,400
+16% +$169K 1.28% 20
2018
Q1
$1.16M Sell
15,425
-13,050
-46% -$1.04M 1.28% 18
2017
Q4
$2.04M Buy
+28,475
New +$2.16M 2.12% 14

Other funds holding GILD

Oak Grove Capital's GILD Position: Q1 2026 in Review

Oak Grove Capital held its Gilead Sciences (GILD) position steady in Q1 2026 at 2,800 shares worth $390K. The position accounts for 0.03% of the portfolio, ranked #78.

Oak Grove Capital first reported a position in GILD in Q4 2017 and has held it in 26 quarters since. The position peaked at $12.9M in Q4 2019. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Oak Grove Capital held 2,800 shares of Gilead Sciences worth $390K as of Q1 2026.
  • Oak Grove Capital left its Gilead Sciences share count unchanged in Q1 2026.
  • Gilead Sciences made up 0.03% of Oak Grove Capital's portfolio in Q1 2026, its #78 holding.
  • Oak Grove Capital first reported a position in Gilead Sciences in Q4 2017 and has held it in 26 quarters since.
  • Oak Grove Capital's Gilead Sciences position peaked at $12.9M in Q4 2019.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Oak Grove Capital's 13F filing for Q1 2026, filed 13 May 2026.